Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The SNM practice guideline for somatostatin receptor scintigraphy 2.0.

Balon HR, Brown TL, Goldsmith SJ, Silberstein EB, Krenning EP, Lang O, Dillehay G, Tarrance J, Johnson M, Stabin MG; Society of Nuclear Medicine..

J Nucl Med Technol. 2011 Dec;39(4):317-24. doi: 10.2967/jnmt.111.098277. No abstract available.

2.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.

Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, Vitek P, Sundin A, Plöckinger U; Mallorca Consensus Conference participants.; European Neuroendocrine Tumor Society..

Neuroendocrinology. 2009;90(2):184-9. doi: 10.1159/000225946. No abstract available.

PMID:
19713709
3.

Clinical relevance of somatostatin receptor imaging.

Reubi JC.

Eur J Endocrinol. 1994 Dec;131(6):575-6. No abstract available.

PMID:
7804438
4.

[Somatostatin receptor scintigraphy].

Rasmussen K, Nielsen JT, Rehling M.

Ugeskr Laeger. 2005 Dec 5;167(49):4647-50. Danish.

PMID:
16336855
5.

Somatostatin receptor imaging with (111)In-pentetreotide in gastro-intestinal tract and lung neuroendocrine tumors-Impact on targeted treatment.

Gerasimou G, Moralidis E, Gotzamani-Psarrakou A.

Hell J Nucl Med. 2010 May-Aug;13(2):158-62. Review.

PMID:
20808990
6.

Updated practice guideline for somatostatin receptor scintigraphy.

Balon HR.

J Nucl Med. 2011 Dec;52(12):1838. doi: 10.2967/jnumed.111.098285. No abstract available.

7.

The SNM practice guideline on hepatobiliary scintigraphy.

Tulchinsky M.

J Nucl Med. 2010 Dec;51(12):1825. doi: 10.2967/jnumed.110.084475. No abstract available.

8.

Somatostatin receptor imaging in patients with neuroendocrine tumors: not only SPECT?

Schillaci O.

J Nucl Med. 2007 Apr;48(4):498-500. No abstract available.

9.

Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.

Slooter GD, Mearadji A, Breeman WA, Marquet RL, de Jong M, Krenning EP, van Eijck CH.

Br J Surg. 2001 Jan;88(1):31-40. Review.

PMID:
11136306
10.

Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.

Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, Donohoe KJ; Society of Nuclear Medicine..

J Nucl Med. 2001 Jul;42(7):1134-8. No abstract available.

11.

Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours.

Savelli G, Lucignani G, Seregni E, Marchianò A, Serafini G, Aliberti G, Villano C, Maccauro M, Bombardieri E.

Nucl Med Commun. 2004 May;25(5):445-9.

PMID:
15100502
12.

Masking effect of chronic pancreatitis in the interpretation of somatostatin receptor positron emission tomography in pancreatic neuroendocrine tumors.

Treglia G, Farchione A, Stefanelli A, Brizi MG, Larghi A, Inzani F, Rindi G, Rufini V.

Pancreas. 2013 May;42(4):726-8. doi: 10.1097/MPA.0b013e3182750ea0. No abstract available.

PMID:
23591437
13.

Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy.

Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M.

Mod Pathol. 2007 Nov;20(11):1172-82.

14.

Radio-guided surgery in neuroendocrine tumors.

Gulec SA, Baum R.

J Surg Oncol. 2007 Sep 15;96(4):309-15. Review.

PMID:
17726664
15.

Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.

Scherübl H, Bäder M, Fett U, Hamm B, Schmidt-Gayk H, Koppenhagen K, Dop FJ, Riecken EO, Wiedenmann B.

Gastroenterology. 1993 Dec;105(6):1705-9.

PMID:
7902821
16.

Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors.

Ezziddin S, Logvinski T, Yong-Hing C, Ahmadzadehfar H, Fischer HP, Palmedo H, Bucerius J, Reinhardt MJ, Biersack HJ.

J Nucl Med. 2006 Feb;47(2):223-33.

17.

[Significance of false-positive findings of somatostatin receptor scintigraphy in diagnosis of neuroendocrine tumors of the gastroenteropancreatic system].

Faiss S, Scherübl H, Bäder M, Fett U, Koppenhagen K, Wiedenmann B, Riecken EO.

Z Gastroenterol. 1994 May;32(5):243-6. German.

PMID:
7915450
18.

Somatostatin-receptor imaging of human malignancies: a new era in the localization, staging, and treatment of tumors.

Kvols LK.

Gastroenterology. 1993 Dec;105(6):1909-11. No abstract available.

PMID:
7902824
19.

Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.

Wiedenmann B, Bäder HM, Scherubl H, Fett U, Zimmer T, Hamm B, Koppenhagen K, Riecken EO.

Semin Oncol. 1994 Oct;21(5 Suppl 13):29-32. No abstract available.

PMID:
7992077
20.

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.

Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, Visser TJ, Krenning EP.

Eur J Nucl Med. 2001 Sep;28(9):1421-9. Review.

PMID:
11585303
Items per page

Supplemental Content

Support Center